Aims: Peroxisome proliferator-activated receptor g (PPARg) agonists reduce blood pressure and vascular injury in hypertensive rodents. Pparg inactivation in vascular smooth muscle cells (VSMC) enhances vascular injury. Transgenic mice overexpressing endothelin (ET)-1 selectively in the endothelium (eET-1) exhibit endothelial dysfunction, increased oxidative stress and inflammation. We hypothesized that inactivation of the Pparg gene in VSMC (smPparg À/À ) would exaggerate ET-1-induced vascular injury.
Aims: Peroxisome proliferator-activated receptor g (PPARg) agonists reduce blood pressure and vascular injury in hypertensive rodents. Pparg inactivation in vascular smooth muscle cells (VSMC) enhances vascular injury. Transgenic mice overexpressing endothelin (ET)-1 selectively in the endothelium (eET-1) exhibit endothelial dysfunction, increased oxidative stress and inflammation. We hypothesized that inactivation of the Pparg gene in VSMC (smPparg À/À ) would exaggerate ET-1-induced vascular injury.
Methods and results: eET-1, smPparg
À/À and eET-1/ smPparg À/À mice were treated with tamoxifen for 5 days and studied 4 weeks later. SBP was higher in eET-1 and unaffected by smPparg inactivation. Mesenteric artery vasodilatory responses to acetylcholine were impaired only in smPparg À/À . N v -Nitro-L-arginine methyl ester abrogated relaxation responses, and the Ednra/Ednrb mRNA ratio was decreased in eET-1/smPparg À/À , which could indicate that nitric oxide production was enhanced by ET-1 stimulation of endothelin type B receptors. Mesenteric artery media/ lumen was greater only in eET-1/smPparg À/À . Mesenteric artery reactive oxygen species increased in smPparg À/À and were further enhanced in eET-1/smPparg À/À . Perivascular fat monocyte/macrophage infiltration was higher in eET- Keywords: hypertension, inflammation, oxidative stress, small arteries, vascular injury Abbreviations: Arg-1, arginase-1; ANOVA, analysis of variance; BP, blood pressure; CD206, mannose receptor; CreER T2 , tamoxifen-inducible Cre recombinase fused with a modified estrogen receptor ligand-binding domain; DHE, dihydroethidium; eET-1, transgenic mice constitutively overexpressing human ET-1 selectively in the endothelium; eNOS, endothelial nitric oxide synthase; ET, endothelin; ET A , endothelin type A; ET B , endothelin type B; FABP4, fatty acid binding protein 4; FOXP3, forkhead box P3; iNOS, inducible nitric oxide synthase; L-NAME, N v -nitro-Larginine methyl ester; MA, mesenteric artery; MCP-1, monocyte chemotactic protein-1; MHC-II, major histocompatibility complex class II; MOMA-2, monocyte/ macrophage antigen-2; NE, norepinephrine; NO, nitric oxide; PPARg, peroxisome proliferator-activated receptor gamma; PVAT, perivascular adipose tissue; ROS, reactive oxygen species; Rps16, ribosomal protein S16; smPparg À/À , inactivation of the Pparg gene in VSMC; SNP, sodium nitroprusside; SOD, superoxide dismutase; TL, tibia length; Treg, T-regulatory lymphocytes; VSMC, vascular smooth muscle cells INTRODUCTION E ndothelin (ET)-1 is a powerful vasoconstrictor peptide produced by endothelial cells that acts on underlying vascular smooth muscle cells (VSMC) to cause contraction and proliferation in VSMC through activation of endothelin type A (ET A ) and endothelin type B (ET B ) receptors. ET-1 also binds on endothelial ET B receptors and promotes vasorelaxation by release of nitric oxide (NO), and prostacyclin [1] . ET-1 contributes to cardiovascular disease by causing endothelial dysfunction and vascular remodeling. Transgenic mice constitutively overexpressing human ET-1 selectively in the endothelium (eET-1) exhibit increased vascular remodeling, oxidative stress and inflammation in the absence of significant blood pressure (BP) changes [2] , whereas mice with inducible endothelial overexpression of human ET-1 present persistent elevation of BP [3] .
Peroxisome proliferator-activated receptor g (PPARg) is a ligand-activated transcription factor that regulates adipogenesis and insulin sensitivity. PPARg ligands include free fatty acids (FA) and thiazolidinedione antidiabetic drugs such as pioglitazone or rosiglitazone. Although PPARg is largely expressed in adipocytes, it is also present in endothelial cells and VSMC. In humans, Pparg-dominant negative mutations are associated with diabetes mellitus, severe insulin resistance and hypertension [4] , whereas treatment with PPARg agonists improve insulin sensitivity and may moderately reduce BP [5] . In hypertensive rodents, PPARg agonists pioglitazone or rosiglitazone reduced BP and improved vascular remodeling and endothelial dysfunction [6] [7] [8] . Heterozygous knockin mice expressing a dominant negative Pparg mutant exhibit cerebral vascular dysfunction and remodeling, suggesting that PPARg is important for vascular homeostasis [9] . Mice with endothelial cell-selective deletion of Pparg have normal BP at baseline and elevated BP under a high-fat diet [10] . Overexpression of a dominant-negative Pparg mutant in VSMC caused hypertension, endothelial dysfunction and hypertrophic remodeling of cerebral arteries [11] . Similarly, VSMC deletion of Pparg exacerbated angiotensin II-induced vascular remodeling and endothelial dysfunction [12] . Interestingly, the antiatherogenic but not antihypertensive effect of pioglitazone was lost in mice with deletion of VSMC Pparg [13] .
There is evidence from in-vitro studies that PPARg activation may counteract ET-1 effects. First, PPARg agonists rosiglitazone and troglitazone dose-dependently inhibit production of ET-1 in endothelial cells by interfering with AP-1-binding activity [14, 15] . Rosiglitazone also inhibits ET-1-induced nuclear factor of kappa light polypeptide gene enhancer in B cells (NFkB) activation of vascular cell adhesion molecule 1, intercellular adhesion molecule 1 and cyclooxygenase-2 expression in rat VSMC [16] and blunts ET-1-induced vasoconstriction ex vivo by upregulating endothelial ET B receptor expression [17] . In vivo, there is only indirect evidence of a protective role for PPARg in ET-1-induced vascular damage. In DOCA-salt hypertensive rats, in which hypertension is in part ET-1-dependent, rosiglitazone prevented BP elevation, endothelial dysfunction, vascular remodeling, reactive oxygen species (ROS) production and vascular production of ET-1 [7] . Thus, it is still unclear whether PPARg modulates ET-1-induced vascular damage in vivo. In addition, the cells responsible for the vascular protective of PPARg activation in models of enhanced ET-1 are still unknown.
We hypothesized that inactivation of the Pparg gene in VSMC (smPparg À/À ) would exaggerate ET-1-induced vascular injury. To test this hypothesis, we evaluated endothelial function and vascular remodeling in a model of endothelial cell-restricted ET-1 overexpression with tamoxifen-inducible VSMC-restricted Pparg deletion. We also investigated vascular oxidative stress and inflammation, as these processes play an important role in causing vascular injury.
MATERIALS AND METHODS

Experimental design
The study was approved by the Animal Care Committee of the Lady Davis Institute for Medical Research and McGill University, and followed recommendations of the Canadian Council for Animal Care. eET-1 were previously described [2] . An inducible tissue-specific Cre/loxP approach was used to ablate Pparg in VSMC [12] . Mice with exon 2 of Pparg flanked by LoxP sites crossed with smCreER T2 mice expressing a tamoxifen-inducible Cre recombinase fused with a modified estrogen receptor ligand-binding domain (CreER   T2   ) , selectively in VSMC, were crossed with eET-1 mice. Ten-to-11-week-old male smCreER T2 , smCreER T2 / eET-1, smCreER T2 /Pparg Flox/Flox and smCreER T2 /eET-1/ Pparg Flox/Flox mice were treated for 5 days with tamoxifen (1 mg/day, subcutaneously) suspended in miglyol 812 (generously provided by Azelis Canada Chemicals Ltd, Scarborough, Ontario, Canada) and studied 4 weeks later. The experimental groups mentioned above will be herein referred to as control (Ctrl), eET-1, smPparg À/À and eET-1/ smPparg À/À , respectively. In a subset of animals, BP was determined by telemetry [3] . Mice mice were anesthetized with 3% isoflurane mixed with O 2 at 1 l/min (depth of anesthesia confirmed by rear foot squeezing), the nonsteroidal anti-inflammatory drug carprofen (20 mg/kg) was administered subcutaneously to minimize the postoperative pain, then surgically instrumented with PA-C10 BP telemetry transmitters (Data Sciences International; Saint Paul, Minnesota, USA). Mice were allowed to recover for 7 days, and carprofen was administered as above once a day for the first 3 days. BP was determined before (baseline) and at weekly intervals after tamoxifen treatment for 5 weeks.
Collection of tissues
At the end of the protocol, mice were weighed, anesthetized with isoflurane as above and blood collected by cardiac puncture on EDTA for ET-1 determination by ELISA (R&D Systems Inc., Minneapolis, Minnesota, USA). The mesenteric artery vascular bed was dissected, and other tissues and tibia harvested in ice-cold phosphate-buffered saline (PBS). Tissues were weighed, and tibia length was determined. Spleen was used for monocyte and T-cell profiling. Second-order mesenteric arteries were used for assessment of endothelial function and vessel mechanics by pressurized myography. Segments of mesenteric artery were embedded in Clear Frozen Section Compound (VWR International; Edmonton, Alberta, Canada) for determination of ROS generation, expression of monocyte chemotactic protein-1 (MCP-1) or evaluation of tissue infiltration and polarization of monocyte/macrophages by immunofluorescence.
For the study of mRNA expression, the total mesenteric artery arcade was removed from the attached intestine under RNase-free conditions and stored immediately in RNAlater (Life Technologies; Burlington, Ontario, Canada). Lymph nodes, lymphatic ducts, connective tissue, nonperivascular fat and veins were removed under the microscope and discarded. The mesenteric artery arcade and perivascular adipose tissue (PVAT) were carefully dissected and stored in RNAlater until RNA extraction. In additional animals, VSMC were isolated from mesenteric artery and cultured for RNA extraction. Briefly, mesenteric arteries were cleaned of adipose and connective tissue, and VSMC were dissociated by the enzymatic digestion (collagenase, elastase and soybean trypsin inhibitor) of vascular arcades. The tissue was filtered and the cell suspension centrifuged and resuspended in DMEM containing heat-inactivated fetal bovine serum (FBS), HEPES, L-glutamine, penicillin and streptomycin. VSMC were cultured in DMEM containing 10% FBS and maintained at 37 8C in a humidified incubator (5% CO 2 /95% air). Early passage cells (passage 2) were used.
The extent of Cre activation was evaluated in reporter mice as previously described [12] . Ten-to-11-week-old male ROSA26
mT-mG/mT-mG and smCreER T2 /ROSA26
mT-mG/mT-mG mice were treated for 5 days with tamoxifen as above and studied 4 weeks later. At the end of the protocol, mice were anesthetized with a 300-375 mg/kg intraperitoneal injection of Avertin [18] . Depth of anesthesia was confirmed by rear foot squeezing. The mice were injected intraperitoneally with heparin (100 United States Pharmacopeia units), then perfused through the left ventricle at a constant pressure of 100 mmHg for 5 min with PBS to remove the blood, followed by 15-min perfusion with 4% paraformaldehyde (PFA). Tissues were collected and incubated in 4% PFA for 24 h with gentle agitation at 4 8C. Tissues were embedded in VWR Clear Frozen Section Compound (VWR International) and stored at À80 8C until used. Mesenteric arteries were stored in PBS at 4 8C until imaged.
Quantification of plasma endothelin-1
Blood samples were centrifuged at 1000 Â g for 15 min at 4 8C to remove blood cells, followed by centrifugation at 10 000 Â g for 10 min at 4 8C to remove platelets. Plasma samples were stored at À80 8C until tested. The concentration of ET-1 was determined in plasma on EDTA using a human ET-1 QuantiGlo ELISA Kit (R&D Systems Inc.).
Assessment of mT and mG expression
The expression of membrane-targeted tandem dimer Tomato (mT) and membrane-targeted green fluorescent protein (mG) was assessed by fluorescence microscopy imaging on intact mesenteric artery segments. Mesenteric artery segments were stained with DRAQ5 (1 mmol/l, Cell Signaling Technology, Danvers, Massachusetts, USA) for 20 min to label the nuclei and washed in PBS three times (20 min each). Mesenteric arteries were mounted in Fluoromount (Sigma-Aldrich; St. Louis, Missouri, USA) and imaged using a Wave FX Spinning Disc Confocal microscope (Quorum Technologies; Guelph, Ontario, Canada).
Functional and morphological vascular studies
Second-order mesenteric artery, of average lumen size $220 mm, were dissected, mounted on a pressurized myograph and endothelial function and vessel mechanics determined as previously described [19] . Vascular contractile properties were assessed by measuring the response to cumulative concentrations of norepinephrine (10 À8 -10 À4 mol/l) and ET-1 (10 À13 -10 À6 mol/l, Bachem; Torrance, California, USA). To evaluate the participation of NO to endothelium-dependent vasorelaxation and ET-1-induced contraction, the dose-response curve to each compound were determined before and after a 20-min preincubation with the NO synthase inhibitor N v -nitro-Larginine methyl ester (L-NAME, 10 À4 mol/l).
Vascular and perivascular reactive oxygen species production
Vascular and PVAT ROS production were assessed on 5-mm cryosections of mesenteric artery by measuring fluorescence after incubation with the ROS-sensitive fluorescent dye dihydroethidium (DHE, 2 mmol/l) in the dark for 1 min at 37 8C.
Fluorescence was visualized and captured with a fluorescence microscope with a CY3 filter as previously described [19] . DHE fluorescence intensity per total surface area was quantified with ImageJ software (National Institute of Mental Health; Bethesda, Maryland, USA) and expressed as fold change relative to control (http://rsb.info.nih.gov/ij/). Images were captured using a fluorescent microscope Leica DM2000 (Leica Microsystems, Richmond Hill, Ontario, Canada) and quantified with ImageJ software. and Arg-1. Sections were washed afterward for three times with TBST, counterstained with DAPI (6 mmol/l; Life Technologies) and mounted with Fluoromount (Sigma-Aldrich).
Evaluation of monocyte chemotactic protein-1 expression and infiltration of monocyte/ macrophages
Images were captured using a Wave FX Spinning Disc Confocal Microscope (Quorum Technologies) and quantified with ImageJ software. Expression of M1 or M2 markers in infiltrating monocyte/macrophages was analyzed in mesenteric artery PVAT by determining the area of each marker within MOMA-2 stained area using color RGB thresholding, and the area of each marker expressed as percentage of MOMA-2 area.
Evaluation of gene expression
The expression of PPARg (Pparg), endothelial NO synthase (eNOS, Nos3), iNOS (Nos2), ET A receptor (Ednra), ET B receptor (Ednrb), superoxide dismutase 1 (Sod1), superoxide dismutase 2 (Sod2), superoxide dismutase 3 (Sod3), NADPH oxidase 1 (Nox1), NADPH oxidase 2 (Cybb), NADPH oxidase 4 (Nox4), adiponectin (Adipoq), FA-binding protein 4 (FABP4, Fabp4) and ribosomal protein S16 (Rps16) mRNA was determined in mesenteric artery, PVAT and/or cultured VSMC by reverse transcription/quantitative PCR (RT-qPCR).
As described above, mesenteric artery and PVAT were dissected and stored in RNAlater. Shortly after, fresh tissues were homogenized for 1 min with a Polytron PT 1600 E homogenizer (Brinkmann Instruments; Mississauga, Ontario, Canada) and processed for total RNA extraction using the mirVana miRNA isolation kit (Life Technologies). Cultured VSMC were lysed using Lysis/Binding Buffer and processed for total RNA extraction as above. RNA concentration was measured using a Nanodrop spectrophotometer ND-100 V3.1.2 (Thermo Fisher Scientific; Wilmington, Delaware, USA). RNA quality was assessed by determining the rRNA and mRNA profile by electrophoresis using an RNAse-free 1% agarose gel submerged in 1X TAE electrophoresis buffer (2 mol/l Tris-acetate and 50 mmol/l EDTA).
After validating the RNA quality of samples, 1, 0.2 and 0.4 mg of total RNA isolated from VSMC, mesenteric artery and PVAT, respectively, were reverse-transcribed with the Quantitect RT kit (Qiagen, Foster City, California, USA). QPCR was performed using the SsoFast EvaGreen 8 Supermix (Bio-Rad Laboratories; Mississauga, Ontario, Canada) with the Mx3005P real-time PCR cycler. Oligonucleotides designed for Pparg, Nos3, Nos2, Ednra, Ednrb, Sod1, Sod2, Sod3, Nox1, Cybb, Nox4, Adipoq, Fabp4 and Rps16 are listed in Supplemental Digital Content Table S1 , http:// links.lww.com/HJH/A750. The qPCR conditions were 2 min at 96 8C, followed by 40 cycles of 5 s at 96 8C and 30 s at 58 8C. Results were normalized with Rps16 and expressed as fold change over control.
Flow cytometry profiling of splenic T cells and monocytes
Profile of T cells and monocyte subtypes was determined by flow cytometry as previously [20] . Single splenocyte suspension was obtained by releasing the splenocytes by forcing pieces of spleen through a 70-mm nylon mesh cell strainer (BD Biosciences) prewet with PBS supplemented with 5% FBS (qualified, Canada origin; Life Technologies) with the back of a 3-ml syringe plunger. The cell strainer was washed with PBS/5% FBS to flush the cells through the nylon mesh. The two previous steps were repeated until only connective tissue remained in the cell strainer. Cells were centrifuged at 300 Â g for 10 min at RT. Cells were resuspended in 5 ml of Red Blood Cell lysis buffer (SigmaAldrich Canada, Oakville, Ontario, Canada) and incubated at RT for 3 min with occasional gentle mixing to eliminate red blood cells. The mixture was diluted with 30 ml of PBS/5% FBS, filtered through a 70-mm nylon mesh cell strainer and centrifuged at 300 Â g for 5 min at RT. Cells were resuspended in 2 ml of PBS/5% FBS and counted using a Z2 Coulter Counter (Beckman-Coulter; Mississauga, Ontario, Canada). Two million cells were stained with a fixable viability dye eFluor 506 (eBioscience; San Diego, California, USA) in PBS, incubated with rat antimouse CD16/CD32 Fc receptor block (clone 2.4G2, BD Biosciences), stained with specific antibodies in PBS/ 5% FBS and analyzed by flow cytometry. Antibodies are listed in Supplemental Digital Content Table S2 for  profiling of T cells and Table S3 for 
on the BD LSRFortessa cell analyzer (BD Biosciences). Fluorescence minus one controls were used to determine fluorescence background and positivity. Data analysis was performed using FlowJo software (Tree Star Inc.; Ashland, Oregon, USA).
Vascular smooth muscle cells isolation and culture
VSMC were isolated as previously described with some modification [21] . Two to three mice per VSMC isolation were used. Mice were anesthetized with isoflurane as above, and the mesenteric artery vascular beds were dissected and collected and stored in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) cell culture medium (Life Technologies) at RT until further processing for VSMC isolation. Mesenteric artery vascular beds were dissected quickly in DMEM/F12 medium to remove the fat under a dissecting microscope. Mesenteric artery vascular beds were digested in 12.5 ml of DMEM/F12 medium containing 25 mg bovine serum albumin (Probumin media grade; EMD Millipore, Billerica, Massachusetts, USA), 25 mg of collagenase type 2 (280 U/mg dry weight; Worthington Biochemical Corporation; Lakewood, New Jersey, USA), 1.5 mg elastase (4.92 U/mg protein; Worthington Biochemical Corporation) and 4.5 mg soybean trypsin inhibitor (Sigma-Aldrich Canada) at 37 8C for 30 min in a 50-ml conical tube with gentle agitation in a hybridization oven (VWR International, LLC; Radnor, Pennsylvania, USA). Digestion efficiency was improved by pipetting up and down the tissue with a 1-ml Raining pipette after the first 10 min of digestion and then after every 5 min. At the end of the digestion, debris were removed by passing the digesta through a 100-mm Falcon cell strainers (VWR International) fitted on top of a 50-ml conical tube. The cell strainers were washed with 5 ml of DMEM/F12 medium. VSMC suspension was centrifuged at 300 Â g for 5 min at RT. VSMC were resuspended in 1 ml of culture medium (DMEM high glucose medium supplemented with 10% heat-inactivated FBS, 100 U/ml of penicillin -streptomycin and 2.8 mmol/l of L-glutamine (all from Life Technologies). A cell suspension aliquot was mixed 1 : 1 with a 0.4% trypan blue solution (Life Technologies), and viable cells were counted with a hemocytometer. VSMC were seeded in 25 cm 2 Falcon Primaria cell culture flasks at a density of 40 000 cells/cm 2 and kept in a humidified 37 8C incubator gassed with 5% CO 2 . Culture medium was changed every 48 h. When cells reached 70-80% confluence, they were trypsinized, washed with culture media and passaged 1 : 3 into 75 cm 2 Falcon Primaria cell culture flasks (passage 1). When cells reached 70-80% confluence, they were lysed using Lysis/Binding Buffer and processed for total RNA extraction as described above.
Data analysis
Results are presented as means AE SEM. Two-way analysis of variance (ANOVA) for repeated measurements followed by a Student-Newman-Keuls post-hoc test evaluated differences among groups in concentration-response curves and BP. All other results were compared using a Student t test or two-way ANOVA followed by a Student-NewmanKeuls post-hoc test. P less than 0.05 was considered statistically significant.
RESULTS
Validation of the animal model and Pparg deletion
We sought to determine the in-vivo efficiency of VSMC Pparg deletion by RT-qPCR. To minimize contamination from other cell types (e.g. endothelial cells, fibroblasts and immune cells), we cultured and compared mesenteric artery VSMC from control and smPparg À/À mice. Expression of Pparg was $70% lower in smPparg À/À compared with control ( Supplemental Fig. S1A 
Physiological parameters
Four weeks after tamoxifen treatment, SBP was increased from 109 AE 2 to 123 AE 5 mmHg in eET-1 compared with control ( Fig. 1) . VSMC Pparg gene disruption did not significantly increase SBP in control mice nor did it FIGURE 1 Endothelin-1 overexpression increased SBP. SBP was assessed by telemetry for 24 h a week before tamoxifen treatment and at weekly intervals thereafter for 5 weeks in control, eET-1, smPparg À/À and eET-1/smPparg À/À mice. Week 0 refers to blood pressure acquired the week prior to tamoxifen treatment, and week 1 refers to blood pressure acquired immediately after the last day of 5 days of tamoxifen treatment. Each point represents the average SBP over a consecutive 24-h period. Data are presented as means AE SEM, n ¼ 4-5. Ã P < 0.05 vs Ctrl. Statistical differences were determined by comparing the blood pressure curves between groups.
exaggerate BP elevation in eET-1 mice. ET-1 overexpression decreased body, heart, liver and total kidney weight to a similar extent in control and smPparg À/À ; however, tibia length was unchanged. smPparg À/À exhibited a decrease of 24% in spleen weight, further decreased by 16% by ET-1 overexpression (Supplemental Table S4 , Supplemental Digital Content, http://links.lww.com/HJH/A750). Plasma ET-1 levels were six-fold higher in eET-1 mice compared with control ( Supplemental Fig. S2 , Supplemental Digital Content, http://links.lww.com/HJH/A750). VSMC Pparg deletion did not alter plasma ET-1 levels in control or eET-1 mice.
Endothelin-1 overexpression preserved endothelium-dependent relaxation in smPparg S/S mice There was no difference in the vasoconstrictor responses of mesenteric artery to norepinephrine or the endotheliumindependent relaxation responses to the NO donor sodium nitroprusside between the groups ( Fig. 2a and d) . Endothelium-dependent relaxation responses to acetylcholine were impaired by 37% in smPparg À/À but not in eET-1 and eET-1/smPparg À/À compared with control (Fig. 2b) . The contribution of NO to endothelium-dependent relaxation determined using the NOS inhibitor L-NAME showed that vasodilatory responses to acetylcholine were decreased to a similar level in all groups (Fig. 2c) . This suggested that normalization of endothelium-dependent relaxation was mediated by increased production of NO.
Endothelin-1 overexpression corrected the enhanced endothelin-1 contraction induced by Pparg deletion
Mesenteric artery from smPparg À/À exhibited enhanced contraction to ET-1 compared with control (Fig. 3a) . Although ET-1 overexpression did not alter the contractile response to ET-1 in control mice, it blunted the increased contractility to ET-1 caused by VSMC Pparg deletion. Blockade of NO generation with L-NAME increased the contractile response to ET-1 in control, eET-1 and eET-1/ smPparg À/À , but not in smPparg À/À (Fig. 3b) .
Effect of vascular smooth muscle cell Pparg deletion and endothelin-1 overexpression on vascular remodeling and stiffness
Media/lumen ratio at 45 mmHg was increased 20% in eET-1/smPparg À/À compared with control (Supplemental Fig.  3A , Supplemental Digital Content, http://links.lww.com/ HJH/A750). Media cross-sectional area was similar between groups (Supplemental Fig. 3B , Supplemental Digital Content, http://links.lww.com/HJH/A750). Mesenteric artery stiffness was increased to the same extent in eET-1, smPparg À/À and eET-1/smPparg À/À compared with control, as indicated by a similar leftward displacement of the stress-strain curves and a 16% decrease in strain at 140 mmHg (Supplemental Fig. 3C , Supplemental Digital Content, http://links.lww.com/HJH/A750).
Vascular smooth muscle cell Pparg inactivation exaggerated endothelin-1-induced oxidative stress VSMC Pparg gene disruption alone increased ROS generation 1.8-fold in mesenteric artery, which was further Endothelin-1 and peroxisome proliferator-activated receptor g
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www.jhypertension.comenhanced 0.7-fold in eET-1/smPparg À/À (Fig. 4) . PVAT ROS generation tended to be higher in eET-1 and smPparg À/À , whereas it was increased three-fold in eET-1/smPparg À/À compared with control. Expression of Sod1 and Sod2 mRNA was similar in all groups, whereas Sod3 mRNA expression was increased similarly in eET-1, smPparg À/À and eET-1/ smPparg À/À compared with control (Supplemental Fig.  S4A -C, Supplemental Digital Content, http://links.lww. com/HJH/A750). Nox4 mRNA expression tended to increase in eET-1/smPparg À/À , whereas Cybb (NADPH oxidase 2) mRNA expression tended to increase in eET-1 (Supplemental Fig. S4D and E, Supplemental Digital Content, http://links.lww.com/HJH/A750).
Effect of vascular smooth muscle cell Pparg gene ablation and endothelin-1 overexpression on inflammation MCP-1 expression in mesenteric artery increased similarly in smPparg À/À and eET-1/smPparg À/À compared with control (Fig. 5b) . Monocyte/macrophage infiltration in mesenteric artery PVAT was $two-fold higher in eET-1 and smPparg À/À compared with control and increased further two-fold in eET-1/smPparg À/À (Fig. 5d) . Polarization of infiltrating monocyte/macrophages was evaluated by the 
FOXP3
þ cells by 26%, with an additional 38% decrease in eET-1/smPparg À/À .
Effect of vascular smooth muscle cell Pparg gene ablation and endothelin-1 overexpression on gene expression
To better understand changes to vascular reactivity, we dissected the mesenteric artery arcade and evaluated the mRNA expression level of several genes. Nos2 (iNOS) mRNA expression was increased two-fold in mesenteric artery of smPparg À/À (Fig. 6a) . ET-1 overexpression increased Nos2 mRNA expression 3.7-fold in mesenteric artery, effect blunted in eET-1/smPparg À/À . Expression of Nos3 (eNOS), the major contributor of vascular NO, was increased 1.2-fold only in eET-1 mice (Fig. 6b) . ET-1 overexpression alone increased ET A and ET B receptor expression ( Fig. 6c and d) . VSMC Pparg inactivation increased ET A and ET B receptor expression to a similar extent in control and eET-1 mice. The ratio of Ednra/Ednrb was decreased by 30% in eET-1/smPparg À/À compared with smPparg À/À (Fig. 6e) . VSMC Pparg inactivation alone increased Nox1 mRNA expression (Fig. 6f) . ET-1 overexpression increased Nox1 expression in control mice, although it did not further increase expression in smPparg À/À mice.
DISCUSSION
These results demonstrate for the first time that Pparg gene disruption in VSMC enhances the contractile response of vessels to ET-1 and exaggerates ET-1-induced oxidative stress, inflammation and vascular remodeling, suggesting that VSMC PPARg counteracts ET-1-induced vascular damage. ET-1 overexpression paradoxically restored endothelium-dependent relaxation and corrected the enhanced contractile response to ET-1 in smPparg À/À mice, despite greater vascular oxidative stress and inflammation.
Validation of smPparg knockout model
PPARg was first described as a nuclear receptor induced during adipocyte differentiation [22] , but gained prominence when identified as the molecular target of the antidiabetic thiazolidinediones [23] . Thiazolidinediones act as high-affinity synthetic agonists of PPARg that improve insulin sensitivity and modestly lower BP in type 2 diabetes mellitus. PPARg has vascular protective effects that extend beyond its role in glucose and lipid metabolism. To investigate the role of VSMC PPARg in ET-1-induced vascular injury, we used the same tamoxifen-inducible tissuespecific Cre/loxP approach that we used previously to study the role of VSMC PPARg in angiotensin II-induced vascular disease [12] . In that study, we showed that smCreER T2 and smCreER T2 /Pparg Flox/Flox mice treated with vehicle, which were used as control, and smCreER T2 mice treated with tamoxifen do not have altered endotheliumdependent relaxation to acetylcholine, indicating that neither tamoxifen nor CreER T2 activation causes impairment in endothelial function. This also demonstrates that effects FIGURE 6 Endothelin-1 overexpression decreased the ratio of endothelin type A to endothelin type B receptors in mesenteric arteries of smPparg À/À mice. The mRNA expression levels of inducible nitric oxide synthase (Nos2), endothelial nitric oxide synthase (Nos3), endothelin type A (Ednra) and endothelin type B (Ednrb) receptors, NADPH oxidase 1 (Nox1) and ribosomal protein S16 (Rps16) were determined by reverse transcription/quantitative PCR in small mesenteric arteries of control, eET-1, smPparg À/À and eET-1/smPparg À/À mice. Data are presented as mean AE SEM, n ¼ 4-6.
seen in tamoxifen-treated smCreER T2 /Pparg Flox/Flox mice are caused by Pparg ablation and not by unexpected effects due to genetic differences. Given the previous results, we have not studied vehicle-treated eET-1/smPparg À/À mice in the current study as it is unlikely that their vascular phenotype will be affected by genetic differences. We have opted for a robust experimental design study in which mice in the four groups expressed CreER T2 in VSMC and were treated with tamoxifen, ruling out effects of tamoxifen treatment and Cre activation. Furthermore, tamoxifen and its metabolites are completely eliminated from the circulation 4.2 days after injection [24] , and tissues from the mice are collected 4 weeks after tamoxifen treatment.
CreER T2 recombinase efficiency was studied using smCreER T2 /ROSA26 mT-mG/mT-mG reporter mice. We found that tamoxifen treatment totally activated CreER T2 recombinase in smooth muscle cells of reporter mice expressing smCreER T2 . Although smooth muscle cells are present in nonvascular tissues such as the gastrointestinal tract, urinary bladder and lung bronchi, it is unlikely that smPparg À/À in these tissues has any impact on vascular function. Using VSMC isolated from smPparg À/À mice, we confirmed the knockout ($70%) of PPARg expression in our model. The residual PPARg expression could originate from other cells such as fibroblasts and endothelial cells that may have survived in the culture.
Peroxisome proliferator-activated receptor g and the vascular system
The current study provides strong evidence that VSMC PPARg activation has beneficial effects on the cardiovascular system independently of its insulin-sensitizing actions. Here, we show that VSMC Pparg inactivation alone is sufficient to cause vascular injury. smPparg À/À impaired endothelial function, enhanced the contractile response to ET-1 and increased stiffness in resistance arteries, associated with increased vascular oxidative stress and MCP-1 levels, as well as enhanced PVAT monocyte/ macrophage infiltration.
Consistent with our previous findings [12] , deleterious effects of VSMC Pparg inactivation were BP-independent. Nevertheless, Chang et al. [25] found that smPparg À/À caused hypotension, whereas Wang et al. [26] reported increased BP in smPparg À/À during the light but not dark cycle. Although each study utilized the Cre/LoxP recombination model, Cre expression was driven by the Sm22a promoter rather than the smMHC promoter in the first two studies. Moreover, both groups have induced smPparg À/À in utero, whereas we did so in adult mice, thereby avoiding potentially confounding developmental effects, which could also explain differences. Chang et al. [27] later reported that smPparg À/À mice completely lack PVAT resulting from the transient activation of the SM22a promoter in PVAT during development.
Human ET-1 overexpression increased SBP significantly in this study, whereas in our previous study, BP rose without achieving statistical significance [2] . In a more recent mouse model with inducible human ET-1 overexpression, SBP rose 30 mmHg [3] , confirming the hypertensive effect of endothelial human ET-1 overexpression. Decreased body, heart, liver and total kidney weight in eET-1mice werenotdue to impaired postnatalgrowth,astibia length was similar in all groups. It is possible that increased endothelium-derived ET-1 in utero caused changes in fetal growth, as the Tie2 promoter has been shown to drive gene expression during embryonic development [28] .
Endothelium-dependent relaxation in small arteries
In rodents and humans, PPARg activation improves NO bioavailability by increasing NO release and through transrepression of pro-oxidant signaling pathways [29] [30] [31] . Here, we extend previous findings by demonstrating that inactivation of PPARg in VSMC impairs endotheliumdependent responses to acetylcholine [12] . Surprisingly, ET-1 overexpression restored relaxation responses in smPparg À/À mice despite enhanced oxidative stress, which reduces NO bioavailability and promotes endothelial dysfunction [32] . The vasodilatory responses to acetylcholine in eET-1/smPparg À/À were largely diminished by the NOS inhibitor L-NAME, suggesting that restoration of relaxation is likely NO-dependent. Although vascular NO is mostly produced by eNOS, we did not find any changes in Nos3 expression in eET-1/smPparg
. Increased Nos3 mRNA in eET-1 may explain why these mice did not present endothelial dysfunction. In eET-1/smPparg À/À , a decrease in ET A /ET B receptor ratio (as shown here by the Ednra/Ednrb mRNA ratio) could contribute to enhanced NO production leading to the paradoxical finding of a preserved endothelial response to acetylcholine in presence of overexpression of ET-1, which results from the consequent shift in the balance of vasodilation and constriction favoring the former. This is interesting in view of evidence that a normal physiological action of ET-1 could indeed be vasodilation as demonstrated in mice with Edn1 gene deletion [33] . In situations of inflammation and oxidative stress, iNOS is upregulated and produces large amounts of NO that typically react with ROS to form ONOO À , worsening the oxidative stress [34] . ET-1 overexpression greatly enhanced the mRNA expression of Nos2 (iNOS) in control mice but not in smPparg
. The absence of iNOS-derived oxidative stress in eET-1/smPparg À/À could have contributed to preserved endothelium-dependent relaxation. mRNA expression of adiponectin, an adipokine that improves endothelial function [35] , and which was decreased in the PVAT of eET-1 and smPparg À/À mice was partially corrected in eET-1/ smPparg À/À , which may have contributed to preservation of vasorelaxation through its anticontractile effects [36, 37] . Although NO seems to play a major role in mediating vasodilatation in eET-1/smPparg À/À , other signaling pathways may participate in the vasodilatory response to acetylcholine. For instance, we previously showed that acetylcholine-induced vasodilation is restored in eET-1 mice deficient in apolipoprotein E and that this effect is mediated by NOS-independent activation of soluble guanylate cyclase and increased activation of 4-aminopyridinesensitive voltage-dependent potassium channels [38] . Alternatively, it is possible that eET-1/smPparg À/À mice have enhanced dismutation of superoxide into hydrogen peroxide, which can act as a mediator of endothelium-dependent vasorelaxation [39] .
Vascular contractile response to endothelin-1
PPARg activation counteracts ET-1-induced vasoconstriction, as shown by Halabi et al. [11] who found that VSMC overexpression of a dominant negative Pparg mutant caused exaggerated contraction of aorta by ET-1. Excess contractility was associated with decreased aortic ET-1 expression and no change in ET A or ET B receptor expression. More recently, Tian et al. [17] demonstrated that rosiglitazone attenuates ET-1-induced aortic contraction by upregulating endothelial ET B receptor expression. In the current study, we found that VSMC Pparg gene inactivation enhanced contractile responses to ET-1 in mesenteric artery. The enhanced contractile responses were not due to general hypercontractility, as concentrationresponse curves to norepinephrine were similar between groups. ET-1 mainly causes contraction by activating ET A receptors, whereas it stimulates vasodilation largely through endothelial ET B receptor-mediated NO release. The enhanced contractile responses to ET-1 in smPparg À/À are unlikely to be due to increased ET A mRNA expression, as eET-1 mice had similar levels with no change in contractility. Blockade of ET B -induced NO production with L-NAME increased the contractile response to ET-1 in all groups except smPparg À/À , providing additional evidence for reduced NO bioavailability in smPparg À/À mice. The absence of any differences between groups after L-NAME treatment also suggests that the enhanced contractile response to ET-1 was caused by reduced NO bioavailability and/or impaired ET B signaling. The enhanced responsiveness to ET-1 induced by VSMC Pparg inactivation was lost in eET-1/smPparg À/À , associated with a decrease in Ednra/ Ednrb, indicating a shift in the balance of vasodilation and constriction favoring the former.
Vascular smooth muscle cell Pparg inactivation exaggerates vascular oxidative stress
The current study demonstrates for the first time that VSMC Pparg inactivation exaggerates ET-1-induced oxidative stress, vascular remodeling and inflammation. eET-1/ smPparg À/À mice presented increased ROS in their mesenteric artery when compared with eET-1 and smPparg À/À mice. Mesenteric artery gene expression of the pro-oxidant enzyme Nox1 was increased to a similar extent in eET-1, smPparg À/À and eET-1/smPparg À/À mice. It is possible that the exaggerated oxidative stress in eET-1/smPparg À/À stems from other sources such as mitochondria. Mesenteric artery gene expression of the antioxidant enzyme Sod3 was also increased to a similar extent in eET-1, smPparg À/À and eET-1/smPparg À/À mice. The expression of Sod3 has been shown by many investigators to be upregulated by pro-oxidant and proinflammatory stimuli as a mechanism to counterbalance increases in oxidative stress. For example, studies have shown that IFN-g and TNF-a upregulate Sod3 mRNA expression levels through activation of NFkB [40, 41] . Likewise, increased levels of pro-oxidant peptides such as ET-1 or angiotensin II also increase Sod3 expression in VSMC [42, 43] .
Vascular smooth muscle cell Pparg inactivation exaggerates vascular remodeling
Enhanced oxidative stress is a common finding in hypertension and is often associated with vascular remodeling.
Eutrophic vascular remodeling was only found in eET-1/ smPparg À/À . Eutrophic remodeling may be an early manifestation of vascular disease, which can progress to more severe hypertrophic remodeling when additional factors such as increased angiotensin II, aldosterone or additional ET-1 are present. Accordingly, the milder vascular damage found in eET-1 mice and smPparg À/À mice may not be sufficient to cause detectable remodeling of small arteries, whereas VSMC Pparg gene inactivation in the presence of increased endothelial ET-1 expression will cause eutrophic vascular remodeling. It is unlikely that vascular remodeling in eET-1/smPparg À/À is due to hemodynamic effects resulting from BP changes, as similar increases in BP were observed in eET-1 mice with no mesenteric artery remodeling.
Vascular inflammation
Vascular inflammation involving both innate and adaptive immune processes play important roles in the pathogenesis of hypertension [44] . Monocyte/macrophage infiltration in PVAT was increased in eET-1 and smPparg À/À and further exaggerated in eET-1/ smPparg À/À . MCP-1 levels in mesenteric artery were also increased in smPparg À/À , although this was not worsened by ET-1 overexpression. Vascular inflammation caused by smPparg À/À could increase migration of inflammatory cells from the spleen to peripheral sites, resulting in decreased spleen weight, found in mice with VSMC Pparg gene inactivation and further enhanced by ET-1 overexpression.
To better understand cellular mediators involved in the inflammatory process, flow cytometry of splenocytes was performed. eET-1/smPparg À/À mice exhibited reduced percentage of anti-inflammatory CD4 þ CD25 þ FOXP3 þ Treg. This was not associated with changes in activated CD4 þ T lymphocytes. Increases in percentages of cells expressing CD11b, marker found on many leukocytes and macrophages, in smPparg À/À mice and enhanced in eET-1/ smPparg À/À , may explain the infiltration of monocytes/ macrophages in the PVAT in eET-1/smPparg À/À . As spleen proinflammatory Ly-6C hi monocytes were increased in eET-1 and smPparg À/À but not eET-1/smPparg À/À , monocyte/ macrophages that have infiltrated the PVAT of eET-1/ smPparg À/À mice could derive from less-inflammatory precursors and have adopted a less-inflammatory phenotype. Accordingly, we hypothesized that there could be a greater fraction of immunomodulatory M2 macrophages than proinflammatory M1 macrophages, which may have contributed to the preserved vasodilatory response to acetylcholine seen in eET-1/smPparg À/À . However, there were no changes in the relative expression of M1 or M2 markers.
In conclusion, these results demonstrate that inducible VSMC Pparg inactivation exaggerates ET-1-induced vascular injury, supporting a protective role for PPARg in hypertension through modulation of pro-oxidant and proinflammatory pathways. Paradoxically, ET-1 overexpression restored endothelium-dependent relaxation and corrected the increased contractile response to ET-1 in smPparg À/À mice, suggesting complex interactions between ET-1 and PPARg within the vasculature.
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